Search

Search Results for "high-dose aflibercept"

High-Dose Aflibercept in the Real World thumbnail

High-Dose Aflibercept in the Real World

Diana Do, MD

High-Dose Aflibercept: 48-Week Data thumbnail

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

High-Dose Aflibercept: Promising Results thumbnail

High-Dose Aflibercept: Promising Results

Lloyd Clark, MD, FASRS

Flexible Dosing for High-Dose Aflibercept: The Data thumbnail

Flexible Dosing for High-Dose Aflibercept: The Data

Diana Do, MD

Extension Data for High-Dose Aflibercept thumbnail

Extension Data for High-Dose Aflibercept

Diana Do, MD

Switch Case: Faricimab to High-dose Aflibercept thumbnail

Switch Case: Faricimab to High-dose Aflibercept

Ash Abbey, MD

Phase 2/3 Data for High-Dose Aflibercept for DME thumbnail

Phase 2/3 Data for High-Dose Aflibercept for DME

David M. Brown, MD

story 1 thumbnail

Trials Examine Use of High-Dose Aflibercept for 12- and 16-Week Dosing for Wet AMD and DME

A Closer Look at 8 mg Aflibercept thumbnail

A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab thumbnail

Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

Ben Young, MD; Pheobe Mellen, MD; and Jordan Deaner, MD

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy thumbnail

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR

Ted Leng, MD; and Michael Klufas, MD

ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE

Philip Storey, MD; and Prof. Sobha Sivaprasad

New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

ARVO Meeting Coverage Day 3: CANDELA and ARCHWAY Data

David Brown, MD and Robert Mittra, MD

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3

Diana Do, MD; and Jennifer Lim, MD

View More